Scientists at Duke-NUS Medical School have uncovered why some pancreatic and colorectal cancers fail to respond to Wnt inhibitors, a promising new class of cancer drugs currently under development for ...
Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.
A new study reveals why some pancreatic and colorectal tumors resist targeted anti-Wnt drugs and suggests how to overcome it, offering new hope to patients with fully treatment-resistant cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results